# Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

> **NCT00139594** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 181 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** licarbazepine

## Key facts

- **NCT ID:** NCT00139594
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00139594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00139594, "Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00139594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*